Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets remain weak
Wed, 5 Feb 01:30 pm

Indian share markets pared early losses in the post-noon trading session, but are trading marginally below the dotted line. Barring FMCG, oil and gas and consumer durables, all the sectoral indices are trading in the green with auto, realty and power stocks being the biggest gainers.

BSE-Sensex is down marginally and NSE-Nifty is trading 4 points up. BSE Mid Cap is trading 0.3% up and BSE Small Cap index is trading up by 0.9%. The rupee is trading at 62.4 to the US dollar.

Majority of the power stocks are trading in the green with Adani Power and Torrent Power being the major gainers whereas Reliance Infa and JaiPrakash Power are among the few stocks trading in the red. As per a leading financial daily, Tata Power is contemplating keeping its annual investment of Rs 15 bn in renewable energy projects in-tact. The company's networth has been eroding due to its flagship coal-based project in Mundra that became unviable after Indonesia changed its coal export laws. Reportedly, the 4,000 MW supercritical project at Mundra has already booked impairment losses of Rs 25 bn. Tata Power has plans of adding 150-200 megawatts of wind and 30 mega watts of solar capacity each year. The company has a total capacity of 8,500 MW out of which 500 MW is from renewable sources. Tata Power has wind-based projects in Maharashtra, Tamil Nadu and Karnataka and will be looking at Madhya Pradesh and Andhra Pradesh as well. The company also has stake in a 240 MW geo-thermal energy project in Indonesia.

Majority of the Indian pharma stocks are trading firm with Elder Pharma and Ranbaxy Labs leading the pack of gainers. However, Ipca Labs and Orchid Chemicals are among the few stocks trading in the red. As per a leading business daily, Mylan has launched the world's first biosimilar version of breast cancer drug Trastuzumab, in India. The product marketed under the brand name HerTrazTM is a biosimilar of Roche's Herceptin. Hertraz was approved by the Drug Controller General of India. The product is available in two strengths 440 mg and 100 mg. Biocon will also be launching its biosimilar version of Trastuzumab this month. Trastuzumab is among the five biologic products that Mylan is developing in partnership with Biocon for the global market. The company has co-exclusive commercialization rights with Biocon for the product in India. Trastuzumab sales in India were estimated at around $21 m for CY12.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain weak". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.